Hamid Malekzadeh

Dr. Hamid Malekzadeh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Global Spine Journal
Verified
Journal Article
Open access
HMHamid Malekzadeh
Hamid Malekzadeh
MGMahdi Golpayegani
Mahdi Golpayegani
ZGZahra Ghodsi
Zahra Ghodsi
MSMohsen Sadeghi-Naini
Mohsen Sadeghi-Naini
MAMohammadhossein Asgardoon
Mohammadhossein Asgardoon
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Study Design: Systematic review. Objective: Providing a comprehensive review of spinal cord injury cost of illness studies to assist health-service planning. Methods: We conducted a systematic review of the literature published from Jan. 1990 to Nov. 2020 via Pubmed, EMBASE, and NHS Economic Evaluation Database. Our primary outcomes were overall direct health care costs of SCI during acute care, inpatient rehabilitation, within the first year post-injury, and in the ensuing years. Results: Through a 2-phase screening process by independent reviewers, 30 articles out of 6177 identified citations were included. Cost of care varied widely with the mean cost of acute care ranging from $290 to $612,590; inpatient rehabilitation from $19,360 to $443,040; the first year after injury from $32,240 to $1,156,400; and the ensuing years from $4,490 to $251,450. Variations in reported costs were primarily due to neurological level of injury, study location, methodological heterogeneities, cost definitions, study populations, and timeframes. A cervical level of the injury, ASIA grade A and B, concomitant injuries, and in-hospital complications were associated with the greatest incremental effect in cost burden. Conclusion: The economic burden of SCI is generally high and cost figures are broadly higher for developed countries. As studies were only available in few countries, the generalizability of the cost estimates to a regional or global level is only limited to countries with similar economic status and health systems. Further investigations with standardized methodologies are required to fill the knowledge gaps in the healthcare economics of SCI.

14 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HMHamid Malekzadeh
Hamid Malekzadeh
ZTZayaan Tirmizi
Zayaan Tirmizi
JAJose Antonio Arellano
Jose Antonio Arellano
FEFrancesco M Egro
Francesco M Egro
AEAsim Ejaz
Asim Ejaz
Burn injuries are a significant global health concern, leading to high morbidity and mortality. Deep burn injuries often result in delayed healing and scar formation, necessitating effective treatment options. Regenerative medicine, particularly cell therapy using adipose-derived stem cells (ASCs), has emerged as a promising approach to improving burn wound healing and reducing scarring. Both in vitro and preclinical studies have demonstrated the efficacy of ASCs and the stromal vascular fraction (SVF) in addressing burn wounds. The application of ASCs for burn healing has been studied in various forms, including autologous or allogeneic cells delivered in suspension or within scaffolds in animal burn models. Additionally, ASC-derived non-cellular components, such as conditioned media or exosomes have shown promise. Injection of ASCs and SVF at burn sites have been demonstrated to enhance wound healing by reducing inflammation and promoting angiogenesis, epithelialization, and granulation tissue formation through their paracrine secretome. This review discusses the applications of adipose tissue derivatives in burn injury treatment, encompassing ASC transplantation, as well as the utilization of non-cellular components utilization for therapeutic benefits. The application of ASCs in burn healing in the future will require addressing donor variability, safety, and efficacy for successful clinical application.

9 October 2023 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SJSeyed Behnam Jazayeri
Seyed Behnam Jazayeri
SKSamuel Berchi Kankam
Samuel Berchi Kankam
AGAli Golestani
Ali Golestani
PSParnian Shobeiri
Parnian Shobeiri
MGMorteza Gholami
Morteza Gholami
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar

4 April 2024 in Surgeries
Verified
Journal Article
Open access
PDF file
SLShawn Jeffrey Loder
Shawn Jeffrey Loder
AVAlexandra M. Vagonis
Alexandra M. Vagonis
Bahaa ShaabanBahaa Shaaban
Bahaa Shaaban
AEAmr Elmeanawy
Amr Elmeanawy
FBFuat Baris Bengur
Fuat Baris Bengur
LKLauren Kokai
Lauren Kokai
Autologous fat grafting, or lipotransfer, is an important surgical approach to relocate adipose tissue within an individual to create volume. While used extensively in plastic and reconstructive surgery, significant drawbacks exist, including unpredictable volume retention. Thus, considerable research has been undertaken to identify surgical or therapeutic approaches that improve outcomes, primarily utilizing a xenograft immunocompromised mouse model. Large animal models are an important step in translating preclinical laboratory studies to the clinic, and previous studies utilizing pigs have been applied successfully for fat grafting research, but protocol variability exists across studies, and no previous publication has adequately described the impact of the swine breed on the experimental outcomes. In this report, we provide information on the critical attributes of the swine fat grafting model, including the following: (1) model selection; (2) donor site and surgical harvest approach; (3) tissue processing; (4) recipient site location and preparation; (5) post-operative care; and (6) longitudinal fat grafting assessments. Our experience comparing the use of Yorkshire and Yucatan breeds in our model showed that Yorkshire adipose tissue was fibrotic, extremely difficult to obtain through liposuction, and labor intensive to process into injectable formats. Alternatively, Yucatan adipose was more similar to human tissue, could be readily obtained through the surgical excision of inguinal fat pads, was amenable to mincing with surgical scissors, and yielded injectable tissue with a 95% efficiency. We determined that generation of a surgical pocket reduced the graft migration and spread, consequently facilitating the graft retrieval without significantly impacting retention. Using 5 cc grafts, the ultimate 3-month volume retention in 16 grafts was 19% ± 17% (or 1.14 cc ± 1.08 cc). While the use of ultrasound did not readily enable graft volume approximation during the study, it was a useful method to visualize the graft placement and ensure injection into the subcutaneous adipose layers.

6 March 2024 in Spinal Cord
Verified
Journal Article
Open access
PDF file
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
MJMohammad-Rasoul Jalalifar
Mohammad-Rasoul Jalalifar
ZGZahra Ghodsi
Zahra Ghodsi
MSMohsen Sadeghi-Naini
Mohsen Sadeghi-Naini
HMHamid Malekzadeh
Hamid Malekzadeh
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Study design A Systematic Review Objectives To determine the therapeutic efficacy of in vivo reprogramming of astrocytes into neuronal-like cells in animal models of spinal cord injury (SCI). Methods PRISMA 2020 guidelines were utilized, and search engines Medline, Web of Science, Scopus, and Embase until June 2023 were used. Studies that examined the effects of converting astrocytes into neuron-like cells with any vector in all animal models were included, while conversion from other cells except for spinal astrocytes, chemical mechanisms to provide SCI models, brain injury population, and conversion without in-vivo experience were excluded. The risk of bias was calculated independently. Results 5302 manuscripts were initially identified and after eligibility assessment, 43 studies were included for full-text analysis. After final analysis, 13 manuscripts were included. All were graded as high-quality assessments. The transduction factors Sox2, Oct4, Klf4, fibroblast growth factor 4 (Fgf4) antibody, neurogenic differentiation 1 (Neurod1), zinc finger protein 521 (Zfp521), ginsenoside Rg1, and small molecules (LDN193189, CHIR99021, and DAPT) could effectively reprogramme astrocytes into neuron-like cells. The process was enhanced by p21-p53, or Notch signaling knockout, valproic acid, or chondroitin sulfate proteoglycan inhibitors. The type of mature neurons was both excitatory and inhibitory. Conclusion Astrocyte reprogramming to neuronal-like cells in an animal model after SCI appears promising. The molecular and functional improvements after astrocyte reprogramming were demonstrated in vivo, and further investigation is required in this field.

4 December 2024 in Global Spine Journal
Verified
Journal Article
Open access
MHMarjan Hesari
Marjan Hesari
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
HMHamid Malekzadeh
Hamid Malekzadeh
RTReza Tabrizi
Reza Tabrizi
MJMohammad-Rasoul Jalalifar
Mohammad-Rasoul Jalalifar
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Study Design: Systematic Review and Meta-Analyses. Objective: To assess the 30- and 90-day readmission rates after a traumatic spinal cord injury (SCI). Methods: A systematic search of MEDLINE and Embase was performed. The period was from inception to June 2022, with no language restrictions. All studies investigating the 30- and/or 90-day readmission rate following traumatic SCI were included. A random-effects model to combine effect sizes in our meta-analysis was applied. Results: Seven out of 2959 reports met eligibility. The mean age of the patients was 50.2 ± 19.9, with a male-to-female ratio of 2.4:1. The most common traumatic SCI was cervical injury (55.3%). The meta-analysis model revealed a 30-day readmission rate of 14.2% after traumatic SCI, with heterogeneity in the studies. The 90-day readmission rate was 35.7%, with homogeneity in the studies. The meta-regression analysis found significant positive associations between cervical and thoracolumbar injuries and patient age and the 30-day readmission rate, while male sex demonstrated a negative association with the 30-day readmission rate. The 30-day readmission rate following index admission was 13.1% and the 30-day readmission rate after rehabilitation facilities was 15.8%. The study found that the 30-day readmission rate in the USA was 14.0%. Conclusions: There is no doubt that readmission is an adverse health outcome. The outcome is also complex and multifaceted, which makes it difficult to predict. Injury level is 1 of the predictors that affect readmission, making it essential to consider factors during discharge planning for high-risk people to reduce 30-day readmission rates.